Start here if you're new
what it is
FMC sells crop chemicals that help farmers kill insects, weeds, and disease across 15 countries.
how it gets paid
Last year Fmc made $3.5B in revenue.
why it's growing
Revenue grew 220.1% last year. The -$13.74 EPS figure matters most because it shows a business that still sells product but is failing badly after gross profit.
what just happened
FMC reported revenue of $1.1B, down 12% vs. prior year, while EPS collapsed to -$13.74.
At a glance
B balance sheet — gets the job done, barely
55/100 earnings predictability — expect surprises
4.2x trailing p/e — the market's not buying it — or you found a deal
2.4% dividend yield — cash in your pocket every quarter
7.0% return on capital — nothing to write home about
xvary composite: 33/100 — weak
What they do
FMC sells crop chemicals that help farmers kill insects, weeds, and disease across 15 countries.
FMC wins because growers do not casually swap chemistry that protects yield. It runs 21 manufacturing facilities in 15 countries, and 76% of sales come from outside the U.S. Scale matters here. You need global distribution, local regulatory approvals, and products farmers already trust when harvest money is on the line.
How they make money
$3.5B
annual revenue · their business grew +220.1% last year
total revenue
$3.5B
+220.1%
The products that matter
manufactures crop protection chemicals
Crop Protection Chemicals
$3.5B revenue
it's the entire $3.5B business, and revenue fell 18.3% last year. If this category stabilizes, the stock can stabilize with it.
100% of revenue
develops plant-health inputs
Plant Health Products
adjacent offering
these products sit next to the core chemicals franchise, but the snapshot gives no separate revenue line. Thin disclosure means you should treat this as support for the core business, not a proven second engine.
watch execution
serves professional pest and turf markets
Professional Pest & Turf Management
non-farm exposure
it broadens end markets beyond row-crop agriculture, but again there is no segment-level revenue in the snapshot. That's useful context, not enough proof to underwrite a separate growth case.
limited visibility
Key numbers
4.2x
trailing p/e
P/E ratio → how many dollars you pay for one dollar of earnings → so what: the market is pricing FMC like earnings are in danger.
$3.3B
long-term debt
Debt equal to 67% of capital is heavy for a company worth roughly $2 billion in the market.
47.0%
operating margin
Operating margin → profit after running the business → so what: the core operation just went badly underwater.
$26
18-month target
That sits about 98% above $13.12, which tells you the stock is priced for deep skepticism, not normal execution.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 15 / 100
- long-term debt $3.3B (67% of capital)
- net profit margin 9.8% — keeps 10 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in FMC 3 years ago → it's now worth $1,180.
The index would have given you $13,920.
source: institutional data · total return
What just happened
missed estimates
FMC reported revenue of $1.1B, down 12% vs. prior year, while EPS collapsed to -$13.74.
Gross margin was still 39.8%, which means the real damage happened below gross profit. The latest reported EPS also missed the $1.34 consensus marker attached to the last quarter's expectations.
$1.1B
revenue
$13.74
eps
39.8%
gross margin
the number that mattered
The -$13.74 EPS figure matters most because it shows a business that still sells product but is failing badly after gross profit.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is a prolonged crop-input demand slump.
high
farmer spending stays weak
FMC sells products farmers buy when planting economics work. Revenue already fell 18.3% last year. Another weak demand cycle would hit the entire $3.5B revenue base.
this risk touches effectively 100% of current revenue.
high
debt limits the margin for error
Long-term debt is $3.3B, or 67% of capital. That's manageable in a healthy earnings environment and less forgiving when price stability is 15/100 and quarterly EPS prints at -$13.74.
more cash may need to go to balance-sheet repair instead of growth.
med
pesticide regulation and product restrictions
This is a regulated chemicals business. If key products face tighter environmental scrutiny, costs can rise and usable product lines can shrink.
the snapshot does not quantify product-level exposure, which is the problem.
med
the cheap multiple could stay cheap
A 4.2x trailing p/e looks optically low, but low multiples do not rerate on vibes. They rerate when revenue, margins, and confidence recover.
if recovery slips, valuation can remain depressed even without another collapse.
the risk picture is simple: a shrinking $3.5B revenue base plus $3.3B of debt leaves very little room for another bad year.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue recovery toward the $4B estimate
Consensus wants revenue to move from $3.5B to $4B. If that rebound does not show up, the low multiple loses its main defense.
earnings
the next quarterly EPS print
After a -$13.74 quarter, you want proof that the latest print was an event, not the new baseline.
risk
debt as a percentage of capital
Debt is already 67% of capital. If operating results stay weak, leverage becomes the story whether management wants it to or not.
trend
institutional selling pressure
Institutions have been net sellers for three straight quarters. If that reverses, sentiment may be stabilizing before the stock price says so.
Analyst rankings
short-term outlook
bottom 5%
momentum score 5 — the lowest rating. in human-speak, analysts expect this to lag most stocks near term.
risk profile
below average
stability score 4 — more volatile than most names. You should expect bigger swings here.
chart momentum
average
technical score 3 — no clear upside signal from the chart yet. The stock has to earn back trust.
earnings predictability
55 / 100
earnings are only moderately predictable. That matters more after a quarter like -$13.74.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 224 buyers vs. 262 sellers in 3q2025. total institutional holdings: 0.1B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$10
$41
$13
current price
$26
target midpoint · +98% from current · 3-5yr high: $50 (+280% · 41% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive